Hexarelin vs Tesamorelin: Comparing the Indexed Record
Researchers comparing Hexarelin and Tesamorelin are usually resolving one question: which compound the published record actually supports for the model in front of them.
Compound profiles
Hexarelin in the indexed record
Indexed output for Hexarelin stands at 313 records, a moderate literature with no registered studies currently listed on ClinicalTrials.gov.
Journals represented in the current index include Drug Target Insights, Endocrine, Eur J Med Res, spanning 2014–2023.
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway — Eur J Med Res, 2023. PMID: 37710348
- The cardiovascular action of hexarelin — J Geriatr Cardiol, 2014. PMID: 25278975
- Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy — Pharmazie, 2019. PMID: 31526442
- Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury — Drug Target Insights, 2021. PMID: 34871336
Tesamorelin in the indexed record
The literature on Tesamorelin is a moderate body of work: 121 PubMed-indexed records, alongside 24 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Ann Pharmacother, BETA, Curr Opin Investig Drugs, spanning 2006–2012.
- Tesamorelin — , 2012. PMID: 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother, 2012. PMID: 22298602
- Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs, 2009. PMID: 19243281
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs, 2011. PMID: 21668043
Classification and why it matters
Hexarelin and Tesamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Hexarelin describes conditions validated for Hexarelin: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tesamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | Hexarelin | Tesamorelin |
|---|---|---|
| PubMed indexed records | 313 | 121 |
| Registered studies (ClinicalTrials.gov) | 0 | 24 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. Hexarelin carries 192 more indexed records than Tesamorelin, which means published methodology, characterisation data and replication attempts are more readily located for Hexarelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 24) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Frequently asked questions
Which of Hexarelin or Tesamorelin has more published research?
Hexarelin, with 313 indexed PubMed records against 121.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are Hexarelin and Tesamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 313 indexed records for Hexarelin and 121 for Tesamorelin.
Related references
- Tesamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.